| 0 (0%) | 06-25 09:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.76 | 1-year : | 12.57 |
| Resists | First : | 9.21 | Second : | 10.76 |
| Pivot price | 8.32  |
|||
| Supports | First : | 8.17 | Second : | 7.53 |
| MAs | MA(5) : | 8.87 |
MA(20) : | 8.33 |
| MA(100) : | 8.07 |
MA(250) : | 9.28  |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 84.2 |
D(3) : | 82.4 |
| RSI | RSI(14): 64.9 |
|||
| 52-week | High : | 12.73 | Low : | 6.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XLO ] has closed below upper band by 11.2%. Bollinger Bands are 48.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.1 - 9.13 | 9.13 - 9.17 |
| Low: | 8.81 - 8.85 | 8.85 - 8.89 |
| Close: | 8.93 - 9.01 | 9.01 - 9.07 |
Thu, 18 Jun 2026
XLO Stock Price, Quote & Chart - ChartMill
Thu, 18 Jun 2026
Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fri, 12 Jun 2026
Daniel Curran reappointed to Class III director at Xilio - TradingView
Fri, 12 Jun 2026
Xilio Therapeutics (XLO) director granted options for 5,000 shares at $7.99 - Stock Titan
Fri, 12 Jun 2026
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options - Stock Titan
Tue, 12 May 2026
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 7 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 28.5 (%) |
| Held by Institutions | 53.5 (%) |
| Shares Short | 165 (K) |
| Shares Short P.Month | 163 (K) |
| EPS | -2.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.78 |
| Profit Margin | -58.6 % |
| Operating Margin | -111.6 % |
| Return on Assets (ttm) | -19.8 % |
| Return on Equity (ttm) | -75.2 % |
| Qtrly Rev. Growth | 331.7 % |
| Gross Profit (p.s.) | 8.12 |
| Sales Per Share | 8.12 |
| EBITDA (p.s.) | -6.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -3.96 |
| PEG Ratio | 0 |
| Price to Book value | 1.15 |
| Price to Sales | 1.1 |
| Price to Cash Flow | -1.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|